180
Participants
Start Date
December 13, 2022
Primary Completion Date
January 11, 2024
Study Completion Date
July 1, 2024
SLN360
SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
Placebo
Sodium chloride, solution for injection
Royal Adelaide Hospital, Adelaide
Monash Health, Melbourne
Linear Clinical Research, Nedlands
Medicus Services SRO, Brandýs nad Labem
Edumed s.r.o., Kardiologicka, endokrinologicka, diabetologicka a interni ambulance Nachod, Náchod
Pratia Pardubice a.s., Pardubice
Endokrinologie Cerny Most s.r.o., Prague
Gentofte Hospital, Hellerup
Regionshospitalet Godstrup, Herning
Viborg Regional Hospital, Viborg
Academic Medical Center - Department of Vascular Medicine, Amsterdam
Onze Lieve Vrouwe Gasthuis, Amsterdam
Bravis Ziekenhuis - Bergen op Zoom, Roosendaal
Universitair Medisch Centrum Utrecht, Utrecht
VieCuri Medisch Centrum, Venlo
Alian, s.r.o., Kardiologicka ambulancia, Bardejov
Kardiomed s.r.o., Lučenec
Iatros International, Bloemfontein
Tiervlei Trial Centre (TTC), Cape Town
TREAD Research - Department of Cardiology, Cape Town
University of Cape Town - Lipid Laboratory, Cape Town
Paarl Research Centre, Paarl
Dr JM Engelbrecht Trial Site, Somerset West
Helderberg Research Institute, Somerset West
Royal Sussex County Hospital, Brighton
Chelsea and Westminster Hospital, London
Panthera - London North, London
Panthera - Manchester, Rochdale
Panthera - Sheffield, Sheffield
Silence Therapeutics plc
INDUSTRY